• Featured Product
  • KD/KO Validated

IL-13RA2 Polyclonal antibody

IL-13RA2 Polyclonal Antibody for IHC, WB, ELISA

Host / Isotype

Rabbit / IgG


human, mouse, rat





Cat no : 11059-1-AP


CD213A2, CT19, IL 13 receptor subunit alpha 2, IL 13R, IL 13R alpha 2, IL 13R subunit alpha 2, IL 13RA2, IL13BP, IL13R, IL13RA2, IL-13RA2, IL13Ralpha2, Interleukin 13 binding protein

Tested Applications

Positive WB detected inHepG2 cells, HeLa cells, rat thymus tissue, rat liver tissue, mouse testis tissue
Positive IHC detected inhuman breast cancer tissue, human brain tissue, human gliomas tissue, human liver cancer tissue, human ovary tumor tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

Western Blot (WB)WB : 1:500-1:1000
Immunohistochemistry (IHC)IHC : 1:50-1:500
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Product Information

11059-1-AP targets IL-13RA2 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen IL-13RA2 fusion protein Ag1534
Full Name interleukin 13 receptor, alpha 2
Calculated molecular weight 380 aa, 44 kDa
Observed molecular weight 65 kDa
GenBank accession numberBC020739
Gene symbol IL13RA2
Gene ID (NCBI) 3598
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

IL13RA2, also named as IL13R and CD213a2, belongs to the type I cytokine receptor family. It binds as a monomer with high affinity to interleukin-13 (IL13), but not to interleukin-4 (IL4). IL13RA2 lacks the cytoplasmic domain for signaling, indicating that it acts as a decoy receptor. IL13RA2 gene polymorphisms have been associated with systemic sclerosis (PMID: 16981293). Overexpression of IL13RA2 gene has been reported in several types of cancer, including melanoma, lung cancer, and brain tumor, which makes it a potential immunotherapeutic target (PMID: 19895199; 24970476; 24021875).


Product Specific Protocols
WB protocol for IL-13RA2 antibody 11059-1-APDownload protocol
IHC protocol for IL-13RA2 antibody 11059-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols



Neuro Oncol

Correction to: Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma

Authors -

J Control Release

In situ targeting nanoparticles-hydrogel hybrid system for combined chemo-immunotherapy of glioma.

Authors - Xiaoqi Wang

Cancer Biol Med

IL13Rα1 prevents a castration resistant phenotype of prostate cancer by targeting hexokinase 2 for ubiquitin-mediated degradation.

Authors - Tingting Feng
  • KD Validated

Front Neurosci

Outer brain barriers in rat and human development.

Authors - Christian B Brøchner

Front Pharmacol

Isorhamnetin Enhances the Radiosensitivity of A549 Cells Through Interleukin-13 and the NF-κB Signaling Pathway.

Authors - Yarong Du

Front Physiol

Downregulation of Interleukin-13 Receptor α2 Inhibits Angiogenic Formation Mediated by Chitinase 3-Like 1 in Late Atherosclerotic Lesions of apoE-/- Mice.

Authors - Qi Xue
  • KD Validated